Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections (NCT06738407) | Clinical Trial Compass
Not Yet RecruitingPhase 4
Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections
United States760 participantsStarted 2026-01-05
Plain-language summary
The goal of this open-label, randomized trial is to assess the efficacy of doxycycline prophylaxis in reducing incidences of bacterial sexually transmitted infections (STIs) among adolescent and young adult females while also evaluating acceptability and antimicrobial resistance in order to inform public health policy.
Who can participate
Age range13 Years – 29 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age 13-29 years, inclusive;
* Self-reports GC, CT, and/or early syphilis diagnosis in the 12 months prior to screening;
* Self-reports condomless (oral, vaginal, and/or anal) intercourse at least once in the 30 days prior to screening
* Is at least 45 kilograms (99.2 pounds) in weight
* Fluent in English (able to read, speak, and understand English);
* Willing to undergo all required study procedures; and
* Willing to provide written informed consent to participate in the study.
Exclusion Criteria:
* Is male;
* Is pregnant, breastfeeding, or planning to become pregnant in the next 12 months;
* Documented history of tetracycline allergy or self-reports an allergy to tetracyclines;
* Current or anticipated use of a medication (e.g., barbiturates, phenytoin, lithium, carbamazepine, systemic retinoids, warfarin) with a contraindicated interaction to doxycycline ;
* Current or planned use of doxycycline for a prolonged period (\> 2 weeks) in the 30 days prior to enrollment, including current prescription for doxycycline for STI prophylaxis;
* Prolonged antibiotic use (\> 2 weeks) within the last 30 days prior to enrollment;
* Co-enrollment in any other concurrent interventional research or studies that may interfere with this study, such as an STI prevention trial, unless approved by Protocol Team in writing;
* Does not have consistent access (or anticipated weekly access for 52 weeks of survey completion) to smartphone that can access the HMP app; or
* An…
What they're measuring
1
Combined incidence of GC, CT, and/or early syphilis infection